Acumen Pharmaceuticals, Inc.
ABOS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABOS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABOS
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech company developing sabirnetug, an investigational antibody targeting soluble amyloid beta oligomers for Alzheimer's disease, with a Phase 2 readout expected by end of 2026.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$211.2M
Cash Runway
18.2 moLead Asset
sabirnetug (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 catalyst for Acumen Pharmaceuticals, Inc..
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech company developing sabirnetug, an investigational antibody targeting soluble amyloid beta oligomers for Alzheimer's disease, with a Phase 2 readout expected by end of 2026.
- Lead candidate sabirnetug targets soluble amyloid beta oligomers for Alzheimer's disease [sec_mda · as of 2026-08-12].
- Cash and equivalents of $59.7M as of 2026-06-30 [sec].
- Net loss of $32.7M for the six months ended 2026-06-30 [sec].
- Accumulated deficit of $394.9M as of June 30, 2025 [sec_mda · as of 2025-08-12].
- Phase 2 topline data for sabirnetug expected by 2026-12-31 [catalyst].
What works
- Focus on a novel mechanism targeting soluble amyloid beta oligomers, which may differentiate from other Alzheimer's therapies [sec_mda · as of 2026-08-12].
- Completed a $35.7M private placement in March 2026 to extend cash runway and support development [sec_mda · as of 2026-05-12].
- Cash and marketable securities of $128.4M as of March 31, 2026, prior to the latest quarter [sec_mda · as of 2026-05-12].
What to weigh
- Substantial doubt about ability to continue as a going concern; cash expected to fund operations only into early 2027 [sec_mda · as of 2026-03-26].
- Net loss of $32.7M for the six months ended 2026-06-30 and accumulated deficit of $394.9M as of June 30, 2025 [sec_mda · as of 2025-08-12].
- Heavy reliance on future capital raises; failure to raise capital could force delay or reduction of programs [sec_mda · as of 2026-05-12].
- No approved products or commercial revenue; expenses expected to increase as sabirnetug advances [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern; cash runway into early 2027
“Based on our current operating plan, we expect that our current balance of cash and cash equivalents and marketable securities will fund our operations into early 2027, but we believe it will not be enough to fund our operations for at least 12 months from the date of issuance of our financial statements included in this Annual Report on Form 10-K. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”
SEC MD&A · March 26, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · sabirnetug — Phase 2 Readout: sabirnetug — Topline data from the Phase 2 trial of sabirnetug in Alzheimer's disease will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash expected to fund operations only into early 2027; substantial doubt exists about ability to continue as a going concern [sec_mda · as of 2026-03-26].
- Clinical trial failure risk — Phase 2 readout for sabirnetug is a binary event; failure could severely impact the company's prospects [catalyst].
- Capital dependency risk — Heavy reliance on future capital raises; failure to raise capital could force delay or reduction of programs [sec_mda · as of 2026-05-12].
- No approved products — No commercial revenue; expenses expected to increase as sabirnetug advances [sec_mda · as of 2025-11-12].
What to watch
- Phase 2 topline data for sabirnetug expected by 2026-12-31 [catalyst].
- Cash burn rate and any additional financing or partnership deals [sec_mda · as of 2026-05-12].
- Updates on preclinical EBD program and nomination of a lead clinical candidate [sec_mda · as of 2026-05-12].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Acumen Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Acumen Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
18.2 months
D/E 1.03 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~123d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$95.2M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 20,992,669 | $49.5M |
| vanguard capital management llc | 3,012,554 | $7.1M |
| alyeska investment group, l.p. | 2,454,754 | $5.8M |
| franklin resources inc | 2,305,096 | $5.4M |
| adar1 capital management, llc | 2,156,334 | $5.1M |
| fmr llc | 1,157,346 | $2.7M |
| hudson bay capital management lp | 968,940 | $2.3M |
| pathstone holdings, llc | 859,110 | $2.0M |
| susquehanna international group, llp | 713,376 | $1.7M |
| millennium management llc | 659,675 | $1.6M |
Showing top 10 of 82 institutional holders of Acumen Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 3.3%
- Days to cover
- 4.0
- Shares short
- 1,675,956
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABOS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Acumen Pharmaceuticals, Inc.?
Acumen Pharmaceuticals, Inc. is a clinical-stage biotech company developing sabirnetug, an investigational antibody targeting soluble amyloid beta oligomers for Alzheimer's disease, with a Phase 2 readout expected by end of 2026.
What is Acumen Pharmaceuticals, Inc.'s lead drug candidate?
Acumen Pharmaceuticals, Inc.'s most advanced tracked candidate is sabirnetug (Phase 2) for early Alzheimer's disease.
What is Acumen Pharmaceuticals, Inc.'s next catalyst?
Acumen Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sabirnetug" — expected December 31, 2026.
Who is the CEO of Acumen Pharmaceuticals, Inc.?
Mr. Daniel J. O'Connell M.B.A. is the chief executive officer of Acumen Pharmaceuticals, Inc. (ABOS).
Where is Acumen Pharmaceuticals, Inc. headquartered?
Acumen Pharmaceuticals, Inc. (ABOS) is headquartered in Newton, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.